A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon

doi:10.3748/wjg.v13.i7.1079

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2604)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

337

HTML

2027

Figures (1-4)

240

Sum=2604

Feb 21, 2007 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (57)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Feb 21, 2007; 13(7): 1079-1084
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1079

Full Size Figure Download Figure

Figure 2 Profiles of the mean ¹³CO₂ breath excretion (▲) and serum TUDCA concentrations (■) plotted against time. Data were collected after administration of the Shellac-coated tablet containing 10% w/w of ¹³C-butyrate and two gelatine capsules containing 250 mg each of TUDCA. Data are expressed as mean ± SD in 12 healthy subjects (A) and 12 Crohn’s disease patients (B).

Citation: Roda A, Simoni P, Magliulo M, Nanni P, Baraldini M, Roda G, Roda E. A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 2007; 13(7): 1079-1084
URL: https://www.wjgnet.com/1007-9327/full/v13/i7/1079.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i7.1079